# Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants

> **NCT05203822** · PHASE1 · COMPLETED · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tepotinib (HydroChloride hydrate)
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT05203822
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-21
- **Primary completion:** 2022-07-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203822, "Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05203822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*